A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) (G0102598)

Is this Study for You?

Let's Get Started!

Description

Assess efficacy and safety of iptacopan compared to placebo and standard of care in adults and adolescents (12-17) with IC-MPGN in native Kidneys

Details
Age

Child to Adult

Eligibility

Age 12-60 at screening, diagnosis of idiopathic IC-MPGN by biopsy within 12 months for adults and within 3 years for adolescents.UPCR >1.0g/g, estimated GFR >= 30 ml/min/1.73m2 at screening, and up to date on vaccines

Locations

Childrens Hospital Colorado
University of Colorado Hospital

Principal Investigator
Photograph of Bradley Dixon

Bradley Dixon

Study ID

Protocol Number: 23-0839

More information available at ClinicalTrials.gov: NCT05755386

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers